Drug-Drug Interactions of β-Adrenoceptor Blockers

Arzneimittel-Forschung/Drug Research

Volumn 53, Issue 12, 2003, Pages 814-822

  Brodde, Otto Erich ^a   Kroemer, Heyo K ^b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY MEDICINE GREIFSWALD   (Germany)

Author keywords

Atenolol; Bisoprolol; Carvedilol; Metoprolol; Adrenoceptor blockers, drug drug interactions

Indexed keywords

ABC TRANSPORTER; ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANESTHETIC AGENT; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CARRIER PROTEIN; CARVEDILOL; CERIVASTATIN; CYTOCHROME P450; CYTOCHROME P450 2D6; DIGITALIS GLYCOSIDE; DIGOXIN; DILTIAZEM; DRUG METABOLIZING ENZYME; GLYCOPROTEIN P; INSULIN; METOPROLOL; MIBEFRADIL; MULTIDRUG RESISTANCE PROTEIN 1; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL ANTIDIABETIC AGENT; STATINE DERIVATIVE; UNINDEXED DRUG; VERAPAMIL;

ALLERGIC ASTHMA; ATRIOVENTRICULAR BLOCK; BINDING AFFINITY; BRADYCARDIA; CARDIOVASCULAR DISEASE; DISEASE EXACERBATION; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FIRST PASS EFFECT; HEART PALPITATION; HUMAN; HYDROPHILICITY; HYPERTENSION; HYPOGLYCEMIA; HYPOTENSION; INTERMITTENT CLAUDICATION; INTRINSIC SYMPATHOMIMETIC ACTIVITY; LIPOPHILICITY; LIVER METABOLISM; RECEPTOR BLOCKING; RECEPTOR SENSITIVITY; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SWEATING; TREMOR; URINARY EXCRETION;

EID: 0346102842     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1299835     Document Type: Review

References (68)

1. Ahlquist, R. P., A study of the adrenotropic receptors. Am. J. Physiol. 153, 586 (1948)
2. Ahmad, S., Metoprolol-Induced Delirium Perpetuated by Propafenone. Am. Fam. Physician 44, 1142 (1991)
3. Bauer, L. A., Horn, J. R., Maxon, M. S. et al., Effect of Metoprolol and Verapamil Administered Separately and Concurrently After Single Doses on Liver Blood Flow and Drug Disposition. J. Clin. Pharmacol. 40, 533 (2000)
4. Baune, B., Furlan, V., Taburet, A. M. et al., In Vitro Effects of Racemates, Separate Enantiomers and Major Metabolites of Mefloquine and Halofantrine on Metoprolol Biotransformation by Rat Liver Microsomes. Xenobiotica 29, 595 (1999)
5. Belpaire, F. M., Wijnant, P., Temmerman, A. et al., The Oxidative Metabolism of Metoprolol in Human Liver Microsomes: Inhibition by the Selective Serotonin Reuptake Inhibitors. Eur. J. Clin. Pharmacol. 54, 261 (1998)
6. Benfield, P., Clissold, S. P., Brogden, R. N., Metoprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders. Drugs 31, 376 (1986)
7. Bennett, P. N., John, V. A., Whitmarsh, V. B., Effect of Rifampicin on Metoprolol and Antipyrine Kinetics. Br. J. Clin. Pharmacol. 13, 387 (1982)
8. Black, J. W., Crowther, A. F., Shanks, R. G. et al., A new adrenergic beta-receptor antagonist. Lancet I, 1080 (1964)
9. Brodde, O.-E., Michel, M. C., Adrenergic and muscarinic receptors in the human heart. Pharmacol. Rev. 51, 651 (1999)
10. 2-adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. Pharmacol. Rev. 43, 203 (1991)
11. Brogden, R. N., Heel, R. C., Speight, T. M. et al., Metoprolol: A review of its pharmacological properties and therapeutic efficacy in hypertension and angina pectoris. Drugs 14, 321 (1977)
12. Bylund, D. B., Eikenberg, D. C., Hieble, P. J. et al., International Union of Pharmacology: nomenclature of adrenoceptors. Pharmacol. Rev. 46, 121 (1994)
13. Dargie, H. J., β Blockers in heart failure. Lancet 362, 2 (2003)
14. Dayer, P., Leeman, T., Marmy, A. et al., Interindividual variation of beta-adrenoceptor blocking drugs, plasma concentration and effect: influence of genetic status on behaviour of atenolol, bopindolol and metoprolol. Eur. J. Clin. Pharmacol. 28, 149 (1985)
15. De Mey, C., Brendel, E., Enterling, D., Carvedilol Increases the Systemic Bioavailability of Oral Digoxin. Br. J. Clin. Pharmacol. 29, 486 (1990)
16. Dunn, C. J., Lea, A. P., Wagstaff, A. J., Carvedilol. A re-appraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs 54, 161 (1997)
17. Gottlieb, S. S., McCarter, R. J., Vogel, R. A., Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N. Engl. J. Med. 339, 489 (1998)
18. Graff, D. W., Williamson, K. M., Pieper, J. A. et al., Effect of Fluoxetine on Carvedilol Pharmacokinetics, CYP2D6 Activity, and Autonomic Balance in Heart Failure Patients. J. Clin. Pharmacol. 41, 97 (2001)
19. Hamelin, B. A., Bouayad, A., Methot, J. et al., Significant Interaction Between the Nonprescription Antihistamine Diphenhydramine and the CYP2D6 Substrate Metoprolol in Healthy Men With High or Low CYP2D6 Activity. Clin. Pharmacol. Ther. 67, 466 (2000)
20. Heel, R. C., Brogden, R. N., Speight, T. M. et al., Atenolol: A review of its pharmacological properties and therapeutic efficacy in angina pectoris and hypertension. Drugs 17, 425 (1979)
21. Hemeryck, A., De Vriendt, C. A., Belpaire, F. M., Metoprolol-Paroxetine Interaction in Human Liver Microsomes: Stereoselective Aspects and Prediction of the in Vivo Interaction. Drug Metab. Dispos. 29, 656 (2001)
22. Hemeryck, A., Lefebvre, R. A., De Vriendt, C. et al., Paroxetine Affects Metoprolol Pharmacokinetics and Pharmacodynamics in Healthy Volunteers. Clin. Pharmacol. Ther. 67, 283 (2000)
23. Horikori, Y., Suzuki, T., Mizobe, M., Pharmacokinetics and metabolism of bisoprolol enantiomers in humans. J. Pharm. Sci. 87, 289 (1998a)
24. Horikori, Y., Suzuki, T., Mizobe, M., Stereoselective metabolism of bisoprolol enantiomers in dogs and humans. Life Sci. 63, 1097 (1998b)
25. Houtzagers, J. J., Streurman, O., Regardh, C. G., The Effect of Pretreatment With Cimetidine on the Bioavailability and Disposition of Atenolol and Metoprolol. Br. J. Clin. Pharmacol. 14, 67 (1982)
26. Jack, D. B., Kendall, M. J., Dean, S. et al., The Effect of Hydralazine on the Pharmacokinetics of Three Different Beta Adrenoceptor Antagonists: Metoprolol, Nadolol, and Acebutolol. Biopharm. Drug Dispos. 3, 47 (1982)
27. Jonsson, O., Behnam-Motlagh, P., Persson, M. et al., Increase in doxorubicin cytotoxicity by carvedilol inhibition of P-glyco-protein activity. Biochem. Pharmacol. 58, 1801 (1999)
28. Kaijser, M., Johnsson, C., Zezina, L. et al., Elevation of Cyclosporin A Blood Levels During Carvedilol Treatment in Renal Transplant Patients. Clin. Transplant. 11, 577 (1997)
29. Keech, A. C., Harper, R. W., Harrison, P. M. et al., Pharmacokinetic Interaction Between Oral Metoprolol and Verapamil for Angina pectoris. Am. J. Cardiol. 58, 551 (1986)
30. Kelly, J. G., Salem, S. A., Kinney, C. D. et al., Effects of Ranitidine on the Disposition of Metoprolol. Br. J. Clin. Pharmacol. 19, 219 (1985)
31. Kendall, M. J., Jack, D. B., Quarterman, C. P. et al., Beta-Adrenoceptor Blocker Pharmacokinetics and the Oral Contraceptive Pill. Br. J. Clin. Pharmacol. 17 (Suppl. 1), 87S (1984)
32. Kim, M., Shen, D. D., Eddy, A. C. et al., Inhibition of the Enantioselective Oxidative Metabolism of Metoprolol by Verapamil in Human Liver Microsomes. Drug Metab. Dispos. 21, 309 (1993)
33. Kirch, W., Kohler, H., Spahn, H. et al., Interaction of cimetdine with metoprolol, propranolol and atenolol. Lancet II, 531 (1981)
34. Kirch, W., Spahn, H., Kohler, H. et al., Interaction of Metoprolol, Propranolol and Atenolol With Concurrent Administration of Cimetidine. Klin. Wochenschr. 60, 1401 (1982)
35. Kirch, W., Spahn, H., Kohler, H. et al., Accumulation and Adverse Effects of Metoprolol and Propranolol After Concurrent Administration of Cimetidine. Arch. Toxicol. (Suppl.) 6, 379 (1983)
36. Kirch, W., Pabst, J., Rose, I. et al., Interaction of bisoprolol with cimetidine and rifampicin. Eur. J. Clin. Pharmacol. 31, 59 (1986)
37. Lancaster, S. G., Sorkin, E. M., Bisoprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris. Drugs 36, 256 (1988)
38. Lancaster, D. L., Adio, R. A., Tai, K. K. et al., Inhibition of Metoprolol Metabolism by Chloroquine and Other Antimalarial Drugs. J. Pharm. Pharmacol. 42, 267 (1990)
39. Lands, A. M., Arnold, A., McAuliff, J. P. et al., Differentiation of receptor systems activated by sympathomimetic amines. Nature 214, 597 (1967)
40. Langer, S. Z., Presynaptic regulation of catecholamine release. Biochem. Pharmacol. 23, 1793 (1974)
41. Leopold, G., Balanced pharmacokinetics and metabolism of bisoprolol. J. Cardiovasc. Pharmacol. 8 (Suppl. 11), S16 (1986)
42. Leopold, G., Kutz, K., Bisoprolol: pharmacokinetic profile. Rev. Contemp. Pharmacother. 8, 35 (1997)
43. Lewis, R. V., Lennard, M. S., Jackson, P. R. et al., Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics Br. J. Clin. Pharmacol. 19, 329 (1985)
44. Lindeberg, S., Holm, B., Lundborg, P. et al., The Effect of Hydralazine on Steady-State Plasma Concentrations of Metoprolol in Pregnant Hypertensive Women. Eur. J. Clin. Pharmacol. 35, 131 (1988)
45. Mangano, D. T., Layug, E. L., Wallace, A. et al., for the Multicenter Study of Perioperative Ischemia Research Group. Effects of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. N. Engl. J. Med. 335, 1713 (1996); Erratum: ibid. 336, 1039 (1997)
46. McDevitt, D. G., In vivo studies on the function of cardiac β-adrenoceptors in man. Eur. Heart J. 10 (Suppl. B), 22 (1989)
47. McGavin, J. K., Keating, G. M., Bisoprolol. A review of its use in chronic heart failure. Drugs 62, 2677 (2002)
48. McLean, A. J., Knight, R., Harrison, P. M. et al., Clearance-Based Oral Drug Interaction Between Verapamil and Metoprolol and Comparison With Atenolol. Am. J. Cardiol. 55, 1628 (1985)
49. McTavish, D., Campoli-Richards, C., Sorkin, E. M., Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 45, 232 (1993)
50. Motomura, S., Zerkowki, H.-R., Daul, A. et al., On the physiologic role of beta-2 adrenoceptors in the human heart: in vitro and in vivo studies. Am. Heart J. 119, 608 (1990)
51. 2-Receptor Antagonists and Beta-Adrenoceptor Blockers. Br. J. Clin. Pharmacol. 17 (Suppl. 1), 51S (1984)
52. Neuhoff, S., Langguth, P., Dressier, C. et al., Affinities at the verapamil binding site of MDR1-encoded P-glycoprotein: drugs and analogs, stereoisomers and metabolites. Int. J. Clin. Pharmacol. Ther. 38, 168 (2000)
53. Poldermans, D., Boersma, E., Bax, J. J. et al., for the Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group, The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. N. Engl. J. Med. 341, 1789 (1999)
54. Poole-Wilson, P. A., Swedberg, K., Cleland, J. G. F. et al., for the COMET Investigators (2003). Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362, 7 (2003)
55. Prakash, A., Markham, A., Metoprolol. A review of its use in chronic heart failure. Drugs 60, 647 (2000)
56. Rau, T., Heide, R., Bergmann, K. et al., Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. Pharmacogenetics 12, 465 (2002)
57. Somer, M., Kallio, J., Pesonen, U. et al., Influence of Hydroxychloroquine on the Bioavailability of Oral Metoprolol. Br. J. Clin. Pharmacol. 49, 549 (2000)
58. Starke, K., Regulation of noradrenaline release by presynaptic receptor systems Rev Physiol Biochem. Pharmacol. 77, 1 (1977)
59. Takara, K., Kakumoto, M., Tanigawara, Y. et al., Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci. 70, 1491 (2002)
60. Tateishi, T., Nakashima, H., Shitou, T. et al., Effect of Diltiazem on the Pharmacokinetics of Propranolol, Metoprolol and Atenolol. Eur. J. Clin. Pharmacol. 36, 67 (1989)
61. 2-Antagonist Interaction. Clin. Pharmacol. Ther. 43, 283 (1988)
62. Wadworth, A. N., Murdoch, D., Brogden, R. N., Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs 42, 468 (1991)
63. Wagner, F., Kalusche, D., Trenk, D. et al., Drug Interaction Between Propafenone and Metoprolol. Br. J. Clin. Pharmacol. 24, 213 (1987)
64. Walley T., Pirmohamed, M., Proudlove, C. et al., Interaction of Metoprolol and Fluoxetine. Lancet 341, 967 (1993)
65. Warren, D. J., Waller, D. G., McAinsh, J., Beta-blockers and renal function. Drugs 25 (Suppl. 2), 108 (1983)
66. Wermeling, D. P., Field, C. J., Smith, D. A. et al., Effects of Long-Term Oral Carvedilol on the Steady-State Pharmacokinetics of Oral Digoxin in Patients With Mild to Moderate Hypertension. Pharmacotherapy 14, 600 (1994)
67. Wuttke, H., Rau, T., Heide, R. et al., Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin. Pharmacol. Ther. 72, 429 (2002)
68. Zhou, H. H., Wood, A. J. J., Stereoselective disposition of carvedilol is determined by CYP2D6. Clin Pharmacol Ther 57, 518 (1995)